Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.

NCT03839524 is registered in ClinicalTrials.gov with Transgene as lead sponsor.

NCT NCT03839524
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03839524 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.
Lead sponsor
Transgene
Phase
Phase 1
Overall status
Completed
Start date
December 9, 2019
Completion date
October 8, 2024
Enrollment
64 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube cancer, ovarian carcinoma, peritoneal carcinoma